Oncogenomics and the development of new cancer therapies (original) (raw)

• Vogelstein, B. & Kinzler, K. W. The Genetic Basis of Human Cancer (McGraw-Hill, New York, 2002).
  Google Scholar
• Balmain, A., Gray, J. & Ponder, B. The genetics and genomics of cancer. Nature Genet. 33 (suppl.), 238–244 (2003).
  Article CAS PubMed Google Scholar
• Popescu, N. C. Comprehensive genetic analysis of cancer cells. J. Cell. Mol. Med. 4, 151–163 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• International Human Genome Sequencing Consotium. Initial sequencing and analysis of the human genome. Nature 409, 860–921 (2001).
• Venter, J. C. et al. The sequence of the human genome. Science 291, 1304–1351 (2001).
  Article ADS CAS PubMed Google Scholar
• Druker, B. J. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol. Med. 8, S14S18 (2002).
• Kim, J. A. Targeted therapies for the treatment of cancer. Am. J. Surg. 186, 264–268 (2003).
  Article CAS PubMed Google Scholar
• Smith, I. E. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies. Anticancer Drugs (suppl. 4), S3–S10 (2001).
• Salgaller, M. Technology evaluation: bevacizumab, Genentech/Roche. Curr. Opin. Mol. Ther. 5, 657–667 (2003).
  CAS PubMed Google Scholar
• Schadt, E. E., Monks, S. A. & Friend, S. H. A new paradigm for drug discovery: integrating clinical, genetic, genomic and molecular phenotype data to identify drug targets. Biochem. Soc. Trans. 31, 437–443 (2003).
  Article CAS PubMed Google Scholar
• Fischer, O. M., Streit, S., Hart, S. & Ullrich, A. Herceptin and Gleevec. Curr. Opin. Chem. Biol. 7, 490–495 (2003).
  Article CAS PubMed Google Scholar
• Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
  Article ADS CAS PubMed Google Scholar
• Bardelli, A. et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300, 949 (2003).
• Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
• Hilgenfeld, E. et al. Spectral karyotyping in cancer cytogenetics. Methods Mol. Med. 68, 29–44 (2002).
  PubMed Google Scholar
• Lucito, R. et al. Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res. 13, 2291–2305 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Cowell, J. K. & Nowak, N. J. High-resolution analysis of genetic events in cancer cells using bacterial artificial chromosome arrays and comparative genome hybridization. Adv. Cancer Res. 90, 91–125 (2003).
  Article CAS PubMed Google Scholar
• Liang, G. et al. DNA methylation differences associated with tumor tissues identified by genome scanning analysis. Genomics 53, 260–268 (1998).
  Article CAS PubMed Google Scholar
• Cottrell, S. E. et al. A real-time PCR assay for DNA-methylation using methylation-specific blockers. Nucleic Acids Res. 32, e10 (2004).
  Article PubMed PubMed Central Google Scholar
• Greshock, J. et al. 1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis. Genome Res. 14, 179–187 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, T. L. et al. Digital karyotyping. Proc. Natl Acad. Sci. USA 99, 16156–16161 (2002).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Wang, T. L. et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc. Natl Acad. Sci. USA 101, 3089–3094 (2004).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Volik, S. et al. End-sequence profiling: sequence-based analysis of aberrant genomes. Proc. Natl Acad. Sci. USA 100, 7696–7701 (2003).
  Article ADS PubMed PubMed Central Google Scholar
• Beroud, C. & Soussi, T. UMD-p53 database: New mutations and analysis tools. Hum. Mutat. 21, 176–181 (2003).
  Article CAS PubMed Google Scholar
• Futreal, P. A. et al. A census of human cancer genes. Nature Rev. Cancer 4, 177–183 (2004).
  Article CAS Google Scholar
• Ramaswamy, S., Ross, K. N., Lander, E. S. & Golub, T. R. A molecular signature of metastasis in primary solid tumors. Nature Genet. 33, 49–54 (2003).
  Article CAS PubMed Google Scholar
• Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418–8423 (2003).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Rosenwald, A. et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198, 851–862 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• van 't Veer, L. J. et al. Expression profiling predicts outcome in breast cancer. Breast Cancer Res. 5, 57–58 (2003).
  Article PubMed Google Scholar
• van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999–2009 (2002).
  Article CAS PubMed Google Scholar
• Nutt, C. L. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 63, 1602–1607 (2003).
  CAS PubMed Google Scholar
• Dyrskjot, L. et al. Identifying distinct classes of bladder carcinoma using microarrays. Nature Genet. 33, 90–96 (2003).
  Article CAS PubMed Google Scholar
• Velculescu, V. E., Zhang, L., Vogelstein, B. & Kinzler, K. W. Serial analysis of gene-expression. Science 270, 484–487 (1995).
  Article ADS CAS PubMed Google Scholar
• Lal, A. et al. A public database for gene expression in human cancers. Cancer Res. 59, 5403–5407 (1999).
  CAS PubMed Google Scholar
• Buckhaults, P. et al. Identifying tumor origin using a gene expression-based classification map. Cancer Res. 63, 4144–4149 (2003).
  CAS PubMed Google Scholar
• Jongeneel, C. V. et al. Comprehensive sampling of gene expression in human cell lines with massively parallel signature sequencing. Proc. Natl Acad. Sci. USA 100, 4702–4705 (2003).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Brentani, H. et al. The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags Proc. Natl Acad. Sci. USA 100, 13418–13423 (2003).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Strausberg, R. L. et al. An international database and integrated analysis tools for the study of cancer gene expression. Pharmacogenomics J. 2, 156–164 (2002).
  Article CAS PubMed Google Scholar
• Saha, S. et al. Using the transcriptome to annotate the genome. Nature Biotechnol. 20, 508–512 (2002).
  Article CAS Google Scholar
• Ota, T. et al. Complete sequencing and characterization of 21,243 full-length human cDNAs. Nature Genet. 36, 40–45 (2004).
  Article PubMed Google Scholar
• Strausberg, R. L. et al. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc. Natl Acad. Sci. USA 99, 16899–16903 (2002).
  Article ADS PubMed Google Scholar
• Xu, Q. & Lee, C. Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences. Nucleic Acids Res. 31, 5635–5643 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, Z. et al. Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer. Cancer Res. 63, 655–657 (2003).
  CAS PubMed Google Scholar
• Kriventseva, E. V. et al. Increase of functional diversity by alternative splicing. Trends Genet. 19, 124–128 (2003).
  Article CAS PubMed Google Scholar
• Strausberg, R. L., Simpson, A. J. & Wooster, R. Sequence-based cancer genomics: progress, lessons and opportunities. Nature Rev. Genet. 4, 409–418 (2003).
  Article CAS PubMed Google Scholar
• Drevs, J., Medinger, M., Schmidt-Gersbach, C., Weber, R. & Unger, C. Receptor tyrosine kinases: the main targets for new anticancer therapy. Curr. Drug Targets 4, 113–121 (2003).
  Article CAS PubMed Google Scholar
• Sausville, E. A., Elsayed, Y., Monga, M. & Kim, G. Signal transduction — directed cancer treatments. Annu. Rev. Pharmacol. Toxicol. 43, 199–231 (2003).
  Article CAS PubMed Google Scholar
• Cockerill, G. S. & Lackey, K. E. Small molecule inhibitors of the class 1 receptor tyrosine kinase family. Curr. Top. Med. Chem. 2, 1001–1010 (2002).
  Article CAS PubMed Google Scholar
• Wilhelm, S. & Chien, D. S. BAY 43-9006: preclinical data. Curr. Pharm. Des. 8, 2255–2257 (2002).
  Article CAS PubMed Google Scholar
• Joensuu, H. & Dimitrijevic, S. Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Ann. Med. 33, 451–455 (2001).
  Article CAS PubMed Google Scholar
• Demetri, G. D. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development. Hematol. Oncol. Clin. North Am. 16, 1115–1124 (2002).
  Article PubMed Google Scholar
• Druker, B. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin. Pharmacother. 4, 963–971 (2003).
  Article CAS PubMed Google Scholar
• Tipping, A. J. & Melo, J. V. Imatinib mesylate in combination with other chemotherapeutic drugs: In vitro studies. Semin. Hematol. 40, 83–91 (2003).
  Article CAS PubMed Google Scholar
• Druker, B. Imatinib alone and in combination for chronic myeloid leukemia. Semin. Hematol. 40, 50–58 (2003).
  Article CAS PubMed Google Scholar
• Joensuu, H. et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 3, 655–664 (2002).
  Article CAS PubMed Google Scholar
• Joensuu, H. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344, 1052–1056 (2001).
  Article CAS PubMed Google Scholar
• GIST SU11248 Study Group. Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Proc. Am. Soc. Clin. Oncol. 22, 814 (abstr. 3273) (2003).
• Egland, K. A., Vincent, J. J., Strausberg, R., Lee, B. & Pastan, I. Discovery of the breast cancer gene BASE using a molecular approach to enrich for genes encoding membrane and secreted proteins. Proc. Natl Acad. Sci. USA 100, 1099–1104 (2003).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Olsson, P., Motegi, A., Bera, T. K., Lee, B. & Pastan, I. PRAC2: a new gene expressed in human prostate and prostate cancer. Prostate 56, 123–130 (2003).
  Article CAS PubMed Google Scholar
• Jager, D. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res. 61, 2055–2061 (2001).
  CAS PubMed Google Scholar
• Bera, T. K. NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate. Proc. Natl Acad. Sci. USA 101, 3059–3064 (2004).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Scanlan, M. J., Gure, A. O., Jungbluth, A. A., Old, L. J. & Chen, Y. T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188, 22–32 (2002).
  Article CAS PubMed Google Scholar
• Scanlan, M. J., Simpson, A. J. & Old, L. J. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 4, 1 (2004).
  PubMed Google Scholar
• Scanlan, M. J. et al. Identification of cancer/testis genes by database mining and mRNA expression analysis. Int. J. Cancer 98, 485–492 (2002).
  Article CAS PubMed Google Scholar
• Old, L. J. Cancer/testis (CT) antigens - a new link between gametogenesis and cancer. Cancer Immun. 1, 1 (2001).
  CAS PubMed Google Scholar
• Durrant, L. G. & Spendlove, I. Cancer vaccines entering Phase III clinical trials. Expert Opin. Emerg. Drugs 8, 489–500 (2003).
  Article CAS PubMed Google Scholar
• Jager, E., Jager, D. & Knuth, A. Antigen-specific immunotherapy and cancer vaccines. Int. J. Cancer 106, 817–820 (2003).
  Article PubMed CAS Google Scholar
• Albanell, J., Codony, J., Rovira, A., Mellado, B. & Gascon, P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv. Exp. Med. Biol. 532, 253–268 (2003).
  Article CAS PubMed Google Scholar
• Blackledge, G. & Averbusch, S. Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors. Br. J. Cancer 90, 566–572 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Coiffier, B. Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly. Semin. Oncol. 30, 21–27 (2003).
  Article CAS PubMed Google Scholar
• Wannesson, L. & Ghielmini, M. Overview of antibody therapy in B-cell non-Hodgkin's lymphoma. Clin. Lymphoma 4 (suppl. 1), S5-S12 (2003).
  Article PubMed Google Scholar
• Jain, R. K. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin. Oncol. 29, 3–9 (2002).
  Article CAS PubMed Google Scholar
• Milenic, D. E. & Brechbiel, M. W. Targeting of radio-isotopes for cancer therapy. Cancer Biol. Ther. 3 (2004).
• Damle, N. K. & Frost, P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr. Opin. Pharmacol. 3, 386–390 (2003).
  Article CAS PubMed Google Scholar
• McCormick, F. Cancer-specific viruses and the development of ONYX-015. Cancer Biol. Ther. 2 (suppl. 1), s157-s160 (2003).
  CAS PubMed Google Scholar
• Tong, A. W., Zhang, Y. A., Cunningham, C., Maples, P. & Nemunaitis, J. Potential clinical application of antioncogene ribozymes for human lung cancer. Clin. Lung Cancer 2, 220–226 (2001).
  Article CAS PubMed Google Scholar
• Moon, C., Oh, Y. & Roth, J. A. Current status of gene therapy for lung cancer and head and neck cancer. Clin. Cancer Res. 9, 5055–5067 (2003).
  CAS PubMed Google Scholar
• McNeish, I. A., Bell, S. J. & Lemoine, N. R. Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes. Gene Ther. 11, 497–503 (2004).
  Article CAS PubMed Google Scholar
• Torrance, C. J., Agrawal, V., Vogelstein, B. & Kinzler, K. W. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nature Biotechnol. 19, 940–945 (2001).
  Article CAS Google Scholar
• Strausberg, R. L. & Schreiber, S. L. From knowing to controlling: a path from genomics to drugs using small molecule probes. Science 300, 294–295 (2003).
  Article ADS CAS PubMed Google Scholar
• Koehler, A. N., Shamji, A. F. & Schreiber, S. L. Discovery of an inhibitor of a transcription factor using small molecule microarrays and diversity-oriented synthesis. J. Am. Chem. Soc. 125, 8420–8421 (2003).
  Article CAS PubMed Google Scholar
• Zerhouni, E. The NIH Roadmap. Science 302, 63–72 (2003).
  Article CAS PubMed Google Scholar
• Collins, F. S., Morgan, M. & Patrinos, A. The Human Genome Project: lessons from large-scale biology. Science 300, 286–290 (2003).
  Article ADS CAS PubMed Google Scholar
• Newman, D. J., Cragg, G. M. & Snader, K. M. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. 66, 1022–1037 (2003).
  Article CAS PubMed Google Scholar
• Myers, N., Mittermeier, R. A., Mittermeier, C. G., da Fonseca, G. A. & Kent, J. Biodiversity hotspots for conservation priorities. Nature 403, 853–858 (2000).
  Article ADS CAS PubMed Google Scholar
• Brizuela, L., Richardson, A., Marsischky, G. & Labaer, J. The FLEXGene repository: Exploiting the fruits of the genome projects by creating a needed resource to face the challenges of the post-genomic era. Arch. Med. Res. 33, 318–324 (2002).
  Article CAS PubMed Google Scholar
• Kretzschmar, T. & von Ruden, T. Antibody discovery: phage display. Curr. Opin. Biotechnol. 13, 598–602 (2002)
  Article CAS PubMed Google Scholar
• Brekke, O. H. & Loset, G. A. New technologies in therapeutic antibody development. Curr. Opin. Pharmacol. 3, 544–550 (2003).
  Article CAS PubMed Google Scholar
• Pasqualini, R. & Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature 380, 364–366 (1996).
  Article ADS CAS PubMed Google Scholar
• Ellerby, H. M. et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nature Med. 5, 1032–1038 (1999).
  Article CAS PubMed Google Scholar
• Scott, A. M. et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 9, 1639–1647 (2003).
  CAS PubMed Google Scholar
• Welt, S. et al. Phase I study of anticolon cancer humanized antibody A33. Clin. Cancer Res. 9, 1338–1346 (2003).
  CAS PubMed Google Scholar
• Scott, A. M. et al. Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial. J. Clin. Oncol. 19, 3967–3987 (2001).
  Article Google Scholar
• Jager, E. et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl Acad. Sci. USA 97, 12198–12203 (2000).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Atanackovic, D. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J. Immunol. 172, 3289–3296 (2004).
  Article CAS PubMed Google Scholar
• Duyk, G. Attrition and translation. Science 302, 603–605 (2003).
  Article ADS CAS PubMed Google Scholar
• Rapisarda, A. et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62, 4316–4324 (2002).
  CAS PubMed Google Scholar